Table 2.

Instances of early (<30 days post-PEX) termination of caplacizumab treatment stratified according to outcome (ie, nonsuccessful [exacerbation, relapse, or death] vs successful [no such event])

Approach	Successful	Nonsuccessful
ADAMTS13 guided	15	0
Platelet count guided	11	9
Total	26	9

An ADAMTS13-guided approach was assumed when a (rising) ADAMTS13 activity >10% was known to the treating physicians at the time of stopping caplacizumab. A platelet count–guided approach was assumed when no such activity measurement was known or activity was still <10% at the time of stopping caplacizumab.